🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Nectar Lifesciences Limited NECLIFE NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.neclife.com
Company Profile ↓
₹11.19
-42.50% 1Y
Mkt Cap₹217.38 Cr
P/E-2.21
P/B0.38
52W High₹22.25
52W Low₹9.30
Book Value₹29.97
EPS (TTM)₹-5.07

Company Overview

Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -98.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR -33.3%, profit CAGR -370.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-33.33%
1 Year:-98.20%

Compounded Profit Growth

5 Years:-370.38%
1 Year:-

Stock Price Performance

1 Year:-42.50%
6 Months:-38.35%
3 Months:-9.83%
1 Month:-5.89%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 15% of range
₹9.30 ₹22.25
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)41.33 · Neutral
Price Performance
1M-5.89%
3M-9.83%
6M-38.35%
1Y-42.50%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -33.3% CAGR over 5 years.
  • Earnings shrank at -370.4% CAGR over 5 years.
  • Trading 49.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-2.21
Industry PE
39.97
Forward P/E
3.77
PEG Ratio
-
Book Value
₹29.97
Price to Book
0.38
P/S
23.19
EV/EBITDA
-3.38
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-33.33%
Profit 5Y
-370.38%
Revenue (YoY)
-98.20%
Earnings (YoY)
-

Profitability & Returns

ROCE
-8.75%
ROE
-50.30%
ROA
-47.12%
Profit Margin
0.00%
Op Margin
-
Gross Margin
100.00%
EPS (Latest Qtr)
₹-3.38
EPS (TTM)
₹-5.07

Balance Sheet & Liquidity

Debt/Equity
0.00
Quick Ratio
8.39
Current Ratio
8.40
Debt
₹0
Total Assets
₹621.61 Cr
Current Assets
₹252.97 Cr
Working Capital
₹222.85 Cr

Ownership

Promoter Holding
55.94%
Chg in Prom Hold
-1.29%
FII / Inst Holding
0.00%
Chg in FII Hold
-0.61%

Financial Snapshot

Enterprise Value
₹217.38 Cr
Total Revenue (TTM)
₹0
EBITDA
₹-28.95 Cr
Free Cash Flow
₹-361.00 Cr
Operating Cash Flow
₹-348.72 Cr
Shares Outstanding
₹19.43 Cr
Gross Margin
100.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NECLIFE Nectar Lifesciences Limited NSEPHARMA 11.19 -2.21 ₹217.38 Cr 0.00% -8.75% -50.30% -33.33% -370.38%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 389.00 Cr394.00 Cr398.00 Cr452.00 Cr441.00 Cr359.00 Cr6.00 Cr-0280.67 Cr5.00 Cr00
Cost of Revenue --------0263.54 Cr3.35 Cr00
Gross Profit --------017.13 Cr1.64 Cr00
Operating Expenses 371.00 Cr359.00 Cr371.00 Cr410.00 Cr393.00 Cr319.00 Cr6.00 Cr-34.03 L95.53 Cr2.17 Cr1.99 Cr57.32 Cr
Operating Income 3.00 Cr21.00 Cr12.00 Cr27.00 Cr33.00 Cr25.00 Cr-1.00 Cr--34.03 L-78.41 Cr-53.24 L-1.99 Cr-57.32 Cr
EBITDA 18.00 Cr36.00 Cr27.00 Cr42.00 Cr48.00 Cr40.00 Cr-1.00 Cr-13.69 L-61.54 Cr-30.21 L86.89 Cr-50.95 Cr
Interest Expense 20.00 Cr18.00 Cr21.00 Cr25.00 Cr24.00 Cr20.00 Cr0-018.70 Cr030.22 Cr5.90 Cr
Pretax Income 2.00 Cr3.00 Cr2.00 Cr2.00 Cr11.00 Cr5.00 Cr5.00 Cr--16.32 L-96.75 Cr-50.62 L56.60 Cr-56.93 Cr
Tax Provision -2.90 Cr1.23 Cr76.00 L72.00 L10.45 Cr2.00 Cr-10.00 L--5.71 L-33.52 Cr-17.69 L-11.02 Cr-19.72 Cr
Net Income 4.00 Cr2.00 Cr1.00 Cr2.00 Cr1.00 Cr3.00 Cr6.00 Cr--130.09 Cr-63.23 Cr-32.93 L14.27 Cr-67.92 Cr
Diluted EPS 0.160.080.050.070.030.130.25--5.80-2.82-7.850.64-3.38

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,638.00 Cr1,674.00 Cr1,635.00 Cr1,874.00 Cr2,779.00 Cr2,363.00 Cr1,541.00 Cr-1,523.67 Cr1,684.09 Cr00
Cost of Revenue --------1,331.43 Cr1,386.88 Cr00
Gross Profit --------192.24 Cr297.21 Cr00
Operating Expenses 1,371.00 Cr1,436.00 Cr1,411.00 Cr1,638.00 Cr2,514.00 Cr2,143.00 Cr1,432.00 Cr-197.42 Cr204.82 Cr78.07 L59.03 Cr
Operating Income 190.00 Cr182.00 Cr162.00 Cr172.00 Cr201.00 Cr159.00 Cr49.00 Cr--5.17 Cr92.38 Cr-78.07 L-59.03 Cr
EBITDA 267.00 Cr239.00 Cr224.00 Cr236.00 Cr264.00 Cr220.00 Cr109.00 Cr-99.50 Cr168.61 Cr63.46 Cr-28.95 Cr
Interest Expense 126.00 Cr123.00 Cr117.00 Cr115.00 Cr148.00 Cr126.00 Cr112.00 Cr-82.80 Cr89.62 Cr036.13 Cr
Pretax Income 85.00 Cr64.00 Cr67.00 Cr63.00 Cr59.00 Cr37.00 Cr-85.00 Cr--42.42 Cr18.27 Cr1.07 Cr-87.88 Cr
Tax Provision 18.70 Cr9.60 Cr12.06 Cr10.71 Cr11.21 Cr5.55 Cr11.90 Cr--18.24 Cr13.27 Cr37.46 L-30.53 Cr
Net Income 66.00 Cr54.00 Cr55.00 Cr52.00 Cr48.00 Cr32.00 Cr-73.00 Cr--24.18 Cr5.00 Cr-113.68 Cr-292.89 Cr
Diluted EPS 2.952.422.472.332.121.42-3.271.12-1.080.22-5.07-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 2,510.00 Cr2,556.00 Cr2,581.00 Cr2,724.00 Cr2,705.00 Cr2,633.00 Cr2,388.00 Cr-2,189.21 Cr2,191.06 Cr2,047.22 Cr621.61 Cr
Current Assets --------1,231.18 Cr1,283.83 Cr1,237.59 Cr252.97 Cr
Cash & Equivalents --------17.55 Cr19.79 Cr19.21 Cr112.13 Cr
Inventory --------672.60 Cr709.15 Cr690.16 Cr29.82 L
Receivables --------279.61 Cr379.19 Cr345.49 Cr0
Total Liabilities --------1,124.62 Cr1,121.80 Cr1,091.11 Cr39.31 Cr
Current Liabilities --------890.93 Cr972.82 Cr1,021.54 Cr30.11 Cr
Long Term Debt --------226.47 Cr140.31 Cr60.13 Cr0
Total Debt 925.00 Cr962.00 Cr878.00 Cr955.00 Cr903.00 Cr779.00 Cr903.00 Cr-753.83 Cr635.54 Cr582.02 Cr0
Total Equity 958.00 Cr954.00 Cr1,006.00 Cr1,058.00 Cr1,105.00 Cr1,136.00 Cr1,062.00 Cr-1,064.59 Cr1,069.25 Cr956.11 Cr582.30 Cr
Shares Outstanding --------22.43 Cr22.43 Cr22.43 Cr19.43 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 144.00 Cr169.00 Cr199.00 Cr65.00 Cr239.00 Cr285.00 Cr21.00 Cr-133.65 Cr224.69 Cr169.44 Cr-348.72 Cr
Investing Cash Flow -60.00 Cr-77.00 Cr-18.00 Cr-29.00 Cr-26.00 Cr-33.00 Cr-29.00 Cr-51.70 Cr-17.02 Cr-41.93 Cr1,208.15 Cr
Financing Cash Flow -61.00 Cr-89.00 Cr-204.00 Cr-40.00 Cr-201.00 Cr-252.00 Cr11.00 Cr--185.58 Cr-205.44 Cr-128.09 Cr-766.51 Cr
Capital Expenditure -80.00 Cr-82.00 Cr-25.00 Cr-33.00 Cr-35.00 Cr-36.00 Cr-31.00 Cr--30.06 Cr-29.41 Cr-43.79 Cr-12.27 Cr
Free Cash Flow 64.00 Cr87.00 Cr174.00 Cr32.00 Cr204.00 Cr249.00 Cr-10.00 Cr-103.59 Cr195.27 Cr125.64 Cr-361.00 Cr
Net Change in Cash 23.00 Cr3.00 Cr-23.00 Cr-4.00 Cr12.00 Cr-04.00 Cr--22.80 L2.23 Cr-58.44 L92.91 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------12.6%17.6%--
Operating Margin % 11.6%10.9%9.9%9.2%7.2%6.7%3.2%--0.3%5.5%--
Net Margin % 4.0%3.2%3.4%2.8%1.7%1.4%-4.7%--1.6%0.3%--
ROE % 6.9%5.7%5.5%4.9%4.3%2.8%-6.9%--2.3%0.5%-11.9%-50.3%
ROCE % ---------0.4%7.6%-0.1%-10.0%

Shareholding Pattern

Insiders
55.94%
Institutions
0.00%
Public Float
0.01%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NECLIFE

Google News ue, 10 Feb 2026

The Market Doesn't Like What It Sees From Nectar Lifesciences Limited's (NSE:NECLIFE) Revenues Yet As Shares Tumble 25% - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPQkRsYTN4TS01QnBYbTZWTGRmNjZvZml0Rmp5WTlhb19FUkZ5RTZQT0pzYlZsbGhoWEJFMms0VmdET1dBVUdRd3ZHUTdqZXEzNzBLSUhsS1dKS2FUSUc2RmY2ZjJWb3pnRnRIME1nemt6Wnk5Q3Z0YjlBRW9HcVlTYjU1ZGNCQzByQlJEcE…

Google News Fri, 28 Nov 2025

Nectar Lifesciences Share Price Rally 19% on Buyback Proposal - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQc2YwV0xqMkhYcXBWcG9iQTBNd3ZaanhIWks5VmtnZFIyS3JoTHdFSTBxR1RoUGtTWFNaSXdDc29hb2xyWDFJbEtqNFFGZHlfTTdZTGRZbUR3WW5Ob2FCQlVDWHdoaVA3OEVqX2d2QW5HOUwtblRRV3BMaG4tRzZVQTRNdFNpV2hNdGpsOA…

Google News Fri, 28 Nov 2025

Nectar Lifesciences shares jump 20% as firm’s board set to consider share buyback on Dec 3 - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOeW5pXzFTanNZeEVwY1VySUpRMUtIZG9vcGdZdnltTUNpYlNJMVVDcm9ab0hmZ1d0QWs2alg1UG9CZDYxX25UMnc2RF9CR1pGSGhWZjA0aGY2ZFJwMFRnTUl3R0w3VFJpVk5ydF9ReHdVcm92c1hEclphaEVFMFVBOXhBMGhWd25hZlFNeH…

Google News hu, 30 Oct 2025

Nectar Lifesciences Insiders Recover Some Losses, Which Stand At ₹11m - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxPZHI1TTRRWGFHR1NJcUY3UFR0bDdyRUpCVE5SWkZJeW5lZ2dxZzhwUW50ZzNPSDQxVkRNRUh4eVN1WUdfQ1lxN3VhRUNxVU14Mmw4bEFsZm5LenFvbkxOQktVaUNvZVFmRVBKY0xGMUpsbGdyWmg4OC0xS24tZ21PWEhrbVUxQkg0b0tFTF…

Google News Wed, 03 Dec 2025

Nectar Lifesciences approves ₹81-crore share buyback; sets record date for Dec 24 - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxOUmNYWFd4ZGNycFhjQXE1TlI2dHR6WjJUQi1Ja3M5d3VKSFplX3V0Qk1rVnJpd3hVbXNrSUs1Tl9JbFpKMHp1YTVDLUNiME9sb3k5N0k4WUt5dVFBN0NEalVaMFloZ0YzWnRMb0FKdnZpc091T1BxOElzX1FfM0I3SDR0bUs5VjJlTEZZa1…

Google News Fri, 28 Jul 2017

NECLIFE Stock Price and Chart — NSE:NECLIFE - TradingView

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9uN2xGTFVUNlp0cGJVOFNNMS16WElaMDczMkJMMzE3QnhrTVdyYk84eExKcVE2RkszQ0RnN2FXSVVRTldKTm5tQjY2RXlseWZJSzJPUXdCeUM5ZGcz?oc=5" target="_blank">NECLIFE Stock Price and Chart — NSE:NECLIFE…

NECLIFE — Frequently Asked Questions

What is the current share price of Nectar Lifesciences Limited (NECLIFE)?

As of 2026-07-15 09:52 IST, Nectar Lifesciences Limited (NECLIFE) trades at ₹11.19 on NSE. Its 52-week range is ₹9.30 to ₹22.25.

What is the market capitalisation of NECLIFE?

Nectar Lifesciences Limited (NECLIFE) has a market capitalisation of ₹217.38 Cr on NSE.

What is the P/E ratio of NECLIFE?

NECLIFE trades at a trailing price-to-earnings (P/E) ratio of -2.21. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 0.38.

What is the return on equity (ROE) of NECLIFE?

NECLIFE has a return on equity (ROE) of -50.30%. Its return on capital employed (ROCE) is -8.75%.

Is NECLIFE a good stock to buy?

This page provides a data-driven analysis of Nectar Lifesciences Limited (NECLIFE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space